Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 987-996

  Siva, A ^a   Xin, H ^a   Qin, F ^a   Oltean, D ^a   Bowdish, K S ^a   Kretz Rommel, A ^a  

^a Alexion Antibody Technologies Inc   (United States)

Author keywords

CD200; Immune evasion; Therapeutic monoclonal antibodies

Indexed keywords

CD200 ANTIGEN; CYTOKINE; LYMPHOCYTE ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; BREAST CANCER; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG CANCER; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MIXED LYMPHOCYTE REACTION; NEUROBLASTOMA; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TH1 CELL; TUMOR CELL; VISCERAL METASTASIS;

ANTIGENS, CD; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA; OVARIAN NEOPLASMS;

EID: 42649112782     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0429-6     Document Type: Article

References (43)

1. Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R et al (2003) Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23(3A):1969-1996
2. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI et al (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103(4):1041-1046
3. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D et al (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178(9):5595-5605
4. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108(13):4194-4197
5. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3):566-568
6. Barclay AN, Clark MJ, McCaughan GW (1986) Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 51:149-157
7. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN (2001) The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102(2):173-179
8. Barclay AN, Wright GJ, Brooke G, Brown MH (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 23(6):285-290
9. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM et al (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290(5497):1768-1771
10. Gorczynski RM, Cattral MS, Chen Z, Hu J, Lei J, Min WP et al (1999) An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163(3):1654-1660
11. Clark DA, Yu G, Levy GA, Gorczynski RM (2001) Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. Semin Immunol 13(4):255-263
12. Gorczynski RM, Chen Z, Clark DA, Kai Y, Lee L, Nachman J et al (2004) Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface. Am J Reprod Immunol 52(2):147-163
13. Freedman LR, Cerottini JC, Brunner KT (1972) In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 109(6):1371-1378
14. Bevan MJ, Cohn M (1975) Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol 114(2 Pt 1):559-565
15. Chattopadhyay S, Chakraborty NG (2005) Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum Immunol 66(8):884-891
16. Tendler CL, Burton JD, Jaffe J, Danielpour D, Charley M, McCoy JP et al (1994) Abnormal cytokine expression in Sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 54(16):4430-4435
17. Takeuchi T, Ueki T, Sasaki Y, Kajiwara T, Li B, Moriyama N et al (1997) Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 43(6):375-381
18. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM (2000) Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44(4):271-274
19. Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J et al (2002) Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49(3):159-166
20. Tabata T, Hazama S, Yoshino S, Oka M (1999) Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg 177(3):203-208
21. Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L (2004) Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 77(8):1138-1144
22. Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Gizzi S, Fioretti MC et al (2004) Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173(6):3748-3754
23. Gorczynski RM, Lee L, Boudakov I (2005) Augmented induction of CD4 + CD25 + Treg using monoclonal antibodies to CD200R. Transplantation 79(4):488-491
24. Mueller JP, Giannoni MA, Hartman SL, Elliott EA, Squinto SP, Matis LA et al (1997) Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 34(6):441-452
25. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 151(1):225-234
26. Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z (2005) Recovery of CD8 + T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 65(15):7000-7006
27. Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ (2005) Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res 11(9):3446-3454
28. Romero P, Cerottini JC, Speiser DE (2006) The human T cell response to melanoma antigens. Adv Immunol 92:187-224
29. Faries MB, Morton DL (2005) Therapeutic vaccines for melanoma: current status. BioDrugs 19(4):247-260
30. Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother (1997) 29(3):233-240
31. Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS et al (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171(9):4650-4654
32. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4):871-881
33. Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL et al (2006) B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66(3):1570-1575
34. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S et al (2006) B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100(1):44-52
35. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793-800
36. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B et al (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119(2):317-327
37. Ichikawa M, Chen L (2005) Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Front Biosci 10:2856-2860
38. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562-567
39. Kacinski BM, Stanley ER, Carter D, Chambers JT, Chambers SK, Kohorn EI et al (1989) Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys 17(1):159-164
40. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr, Brown EL (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83(3):921-926
41. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB et al (1993) Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53(8):1939-1944
42. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR (2005) The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 92(7):1182-1187
43. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12(12):1005-1016